半剂量并递减依那西普联合常规用药治疗强直性脊柱炎的短期临床观察

目的：探讨半剂量并递减依那西普（etanercept）联合常规用药治疗强直性脊柱炎（AS）的有效性和安全性。方法：采集100例活动性AS患者随机分为两组，常规治疗组50例，给予甲氨蝶呤＋羟氯喹＋柳氮磺胺吡啶＋非甾体类消炎止痛药；依那西普联合治疗组50例，给予常规治疗组药物＋依那西普（用法为：第1～4周，每次25mg，皮下注射，每周1次；第5～8周，每次12．5mg，皮下注射，每周1次；第9～12周，每次12．5mg，皮下注射，每10天1次）。分别于用药0，4，8，12周采用ASAS推荐的评价标准和ESR、CRP炎性指标评估临床疗效。结果：依那西普联合治疗组于4，8，12周达到ASAS20反应患者比例显著高于常规治疗组（P〈0．05）.依那西普联合治疗组4周时，总体评分改善率明显高于常规治疗组（P〈O．05）；12周时，脊柱病评分改善程度明显高于常规治疗组（P〈0．05）.12周时依那西普联合治疗组的指地距测量、ESR和CRP炎性指标降低程度也明显高于常规治疗组（P〈0．05）。两组患者的不良反应发生率差异无显著统计学意义（P〉0．05）.结论：半剂量并递减依那西普联合常规用药治疗活动性AS的短期，临床疗效及安全性优于常规治疗。

A short-term study on half-value dose and decrement etanercept plus conventional therapy in active ankylosing spondylitis

Objective: To evaluate the efficacy and safety of half-value dose and decrement etanercept plus conventional therapy in ankylosing spondylitis (AS). Methods: 100 Patients with active AS were randomized into two groups: the control group, including 50 patients, received conventional therapy (methotrexate + hydroxychloroquine + sulfasalazine + nonsteroidal antiinflammatory drug) and the test group, including 50 patients, received conventional drugs plus etanercept (25 mg, hypodermic injection, once a week for...